SLAMF1 and B-cell chronic lymphocytic leukemia: For instance, in CLL, low expression of SLAMF1/CD150 by pathological B cells was associated with an adverse prognosis, whereas in DLBCL, its high expression was linked to resistance to chemotherapy.